Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 15/20 | 1.00 |
| ▸ | LDHB | P07195 | 14/20 | 1.00 |
| ▸ | ALB | P02768 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233361 | 0.84 | LDHA (1.00) | LDHALDHBPTPN1 | |
| SCHEMBL2754182 | 0.84 | LDHA (0.71) | LDHALDHBALBPTPN1PTPN11 | |
| SCHEMBL30417934 | 0.84 | LDHA (1.00) | LDHALDHBPTPN1 | |
| SCHEMBL7174623 | 0.83 | LDHA (1.00) | LDHALDHBALBPTPN1PTPN11 | |
| SCHEMBL7179530 | 0.82 | LDHA (0.87) | LDHALDHBALB | |
| SCHEMBL7187931 | 0.82 | LDHA (0.87) | LDHALDHBALB | |
| SCHEMBL7185727 | 0.78 | LDHA (0.78) | LDHALDHB | |
| SCHEMBL7186222 | 0.77 | LDHA (0.62) | LDHALDHBPTPN1PTPN11 | |
| SCHEMBL7183958 | 0.75 | LDHA (1.00) | LDHALDHBALBCYP3A4ACHE | |
| SCHEMBL15841763 | 0.75 | LDHA (0.59) | LDHALDHBPTPN1PTPN11JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010002465-A2 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002465-A2 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-0980350-A4 | HYDROXYNAPHTHOIC ACIDS AND DERIVATIVES | UNIV NEW MEXICO (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6124498-A | Hydroxynaphthoic acids and derivatives | UNIVERSITY OF NEW MEXICO (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0980350-A2 | HYDROXYNAPHTHOIC ACIDS AND DERIVATIVES | The University of New Mexico (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049130-A2 | HYDROXYNAPHTHOIC ACIDS AND DERIVATIVES | THE UNIVERSITY OF NEW MEXICO (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | LDHA 9/4885LDHB 6/4885ALB 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.